A fusion protein is a protein composed of at least two domains that are encoded by separate genes fused together so that they are transcribed and translated as a single unit, producing a single polypeptide.

Context Therapeutics has revealed promising preclinical results for its research asset, CTIM-76.

This article summarized the latest R&D progress of Glycyrrhetinic Acid, the mechanism of action for Glycyrrhetinic Acid, and the drug target R&D trends for Glycyrrhetinic Acid.

Chimeric Therapeutics has disclosed that the US FDA has given the green light to the IND submission for CHM 2101.

According to the Patsnap Bio Sequence Database, the top 10 applicants for the Vyjuvek patent are Krystal Biotech with 32 applications, Holostem Terapie Avanzate Srl with 6 applications, and FONDATION A DE ROTHSCHILD with 2 applications.

AceLink Therapeutics announced the initiation of AL01211 dosage for the first patient in its Phase 2 study for Fabry disease in China.

This article summarized the latest R&D progress of Halcinonide, the Mechanism of Action for Halcinonide, and the drug target R&D trends for Halcinonide.

Nimbus Therapeutics, LLC has now shared preliminary findings from its ongoing Phase 1/2 trial of NDI-101150, an HPK1 small-molecule inhibitor.

Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Immunology firm, INmune Bio, Inc. will present its findings on the use of INB03 in managing high-risk MUC4 expressing HER2+ breast cancer. INB03 is a dominant-negative suppressor of soluble TNF.

This article summarized the latest R&D progress of Hydrocortisone Sodium Succinate, the Mechanism of Action for Hydrocortisone Sodium Succinate, and the drug target R&D trends for Hydrocortisone Sodium Succinate.

Sarepta Therapeutics, Inc. shared initial results from EMBARK, a global Phase 3 trial evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in Duchenne muscular dystrophy patients aged 4-7.